XBIOTECH INC. Cost of Revenue
XBIOTECH INC. (XBIT) reported Cost of Revenue of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2024-03-15
- XBIOTECH INC. cost of goods and services sold for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. cost of goods and services sold for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. cost of goods and services sold for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. cost of goods and services sold for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. cost of goods and services sold for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- XBIOTECH INC. cost of goods and services sold for fiscal 2022 was $651.00K, a 88.81% decline from fiscal 2021.
- XBIOTECH INC. cost of goods and services sold for fiscal 2021 was $5.82M, a 83.15% decline from fiscal 2020.
- XBIOTECH INC. cost of goods and services sold for fiscal 2020 was $34.55M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $0.00 10-K · filed 2024-03-15 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $16.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-11 | $0.00 10-Q · filed 2023-08-11 | $16.00K derived: sum of 3 quarters · filed 2024-03-15 | $231.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $16.00K derived: sum of 2 quarters · filed 2024-03-15 | $231.00K derived: sum of 3 quarters · filed 2024-03-15 | $438.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $231.00K derived: sum of 2 quarters · filed 2024-03-15 | $438.00K derived: sum of 3 quarters · filed 2024-03-15 | $651.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | $215.00K 10-Q · filed 2023-11-09 | $422.00K derived: sum of 2 quarters · filed 2023-11-09 | $635.00K 10-Q · filed 2023-11-09 | $1.68M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $207.00K 10-Q · filed 2023-08-11 | $420.00K 10-Q · filed 2023-08-11 | $1.47M derived: sum of 3 quarters · filed 2023-08-11 | $2.58M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $213.00K 10-Q · filed 2023-05-10 | $1.26M derived: sum of 2 quarters · filed 2023-05-10 | $2.37M derived: sum of 3 quarters · filed 2023-05-10 | $3.73M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.16M derived: sum of 2 quarters · filed 2023-03-15 | $3.52M derived: sum of 3 quarters · filed 2023-03-15 | $5.82M 10-K · filed 2023-03-15 |
| 2021-09-30 | $1.11M 10-Q · filed 2022-11-09 | $2.47M derived: sum of 2 quarters · filed 2022-11-09 | $4.77M 10-Q · filed 2022-11-09 | $7.02M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.36M 10-Q · filed 2022-08-10 | $3.66M 10-Q · filed 2022-08-10 | $5.91M derived: sum of 3 quarters · filed 2022-08-10 | $15.34M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $2.30M 10-Q · filed 2022-05-10 | $4.55M derived: sum of 2 quarters · filed 2022-05-10 | $13.98M derived: sum of 3 quarters · filed 2022-05-10 | $27.18M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $11.67M derived: sum of 2 quarters · filed 2022-03-15 | $24.88M derived: sum of 3 quarters · filed 2022-03-15 | $34.55M 10-K · filed 2022-03-15 |
| 2020-09-30 | $9.43M 10-Q · filed 2021-11-09 | $22.63M derived: sum of 2 quarters · filed 2021-11-09 | $32.30M 10-Q · filed 2021-11-09 | $32.30M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $13.20M 10-Q · filed 2021-08-09 | $22.88M 10-Q · filed 2021-08-09 | $22.88M derived: sum of 3 quarters · filed 2022-03-15 | $22.88M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $9.67M 10-Q · filed 2021-05-10 | $9.67M derived: sum of 2 quarters · filed 2022-03-15 | $9.67M derived: sum of 3 quarters · filed 2022-03-15 | $9.67M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |